This objectives of this study are to evaluate the safety, tolerability, and pharmacokinetics of a single dose of nusinersen (ISIS 396443) administered intrathecally to participants with Spinal Muscular Atrophy (SMA).
This study was conducted and the protocol was registered by Ionis Pharmaceuticals, Inc. In August 2016, sponsorship of the trial was transferred to Biogen.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
28
Administered by intrathecal (IT) injection
Children's Hospital Boston
Boston, Massachusetts, United States
Columbia University Medical Center
New York, New York, United States
UT Southwestern Medical Center - Children's Medical Center Dallas
Dallas, Texas, United States
University of Utah School of Medicine
Salt Lake City, Utah, United States
Number of participants that experience Adverse Events (AEs) and Serious Adverse Events
Time frame: Up to 88 Days
Number of participants with clinically significant neurological examination abnormalities
Time frame: Up to 88 Days
Number of participants with clinically significant vital sign abnormalities
Time frame: Up to 88 Days
Number of participants with clinically significant physical examination abnormalities
Time frame: Up to 88 Days
Number of participants with clinically significant weight abnormalities
Time frame: Up to 88 Days
Number of participants with clinically significant laboratory parameters
Time frame: Up to 88 Days
Number or participants with clinically significant cerbrospinal fluid (CSF) laboratory parameters
Time frame: Up to 88 Days
Number of participants with clinically significant electrocardiograms (ECGs) abnormalities
Time frame: Up to 88 Days
Number of participants who use concomitant medications
Time frame: Up to 88 Days
PK parameters of nusinersen (ISIS 396443): Maximum observed plasma drug concentration (Cmax)
Time frame: Plasma at 1, 2, 4 and 20 hours after dosing
PK parameters of nusinersen: Time to reach maximum observed concentration (Tmax)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Plasma at 1, 2, 4 and 20 hours after dosing
PK parameters of nusinersen: Area under the plasma concentrations time curve from the time of the intrathecal (IT) dose to the last collected sample (AUCinf)
Time frame: Plasma at 1, 2, 4 and 20 hours after dosing
PK parameters of nusinersen (ISIS 396443): Apparent terminal elimination half-life (t1/2), if possible
Time frame: Plasma at 1, 2, 4 and 20 hours after dosing